Navigation Links
Gene fusions may be the 'smoking gun' in prostate cancer development, U-M study finds
Date:5/18/2010

ANN ARBOR, Mich. Prostate cancer treatments that target the hormone androgen and its receptor may be going after the wrong source, according to a new study. Researchers have found that when two genes fuse together to cause prostate cancer, it blocks the receptor for the hormone androgen, preventing prostate cells from developing normally.

The study, from the University of Michigan Comprehensive Cancer Center, suggests that the gene fusion not the androgen receptor is a more specific "bad actor" in prostate cancer and is the real smoking gun that should be targeted by treatments.

"We need to begin to think about targeting prostate cancer by targeting the gene fusion, and not confining our approaches to androgen receptor. If we're going to find a more durable therapy, we need to get at the gene fusion," says study author Arul Chinnaiyan, M.D. Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Endowed Professor of Pathology at the U-M Medical School. Chinnaiyan is also a Howard Hughes Medical Institute investigator and an American Cancer Society research professor.

The study is featured on the cover of the May 18 issue of Cancer Cell.

Treatments for prostate cancer typically include drugs to moderate androgen, a male hormone that controls the normal growth of the prostate. These drugs typically work at first, but over time the cancer cells become resistant to the therapy and the cancer returns. Because it's no longer responsive to currently available hormone deprivation therapies, the recurrent cancer is usually more difficult to treat.

In 2005, Chinnaiyan and his team identified a prostate-specific gene called TMPRSS2 that fuses with a cancer-causing gene called ERG. The team's earlier research has shown that this gene fusion acts as an "on switch" to trigger prostate cancer.

This new study used sophisticated sequencing technologies to map the genome-wide location of androgen receptor and the TMPRSS2-ERG gene fusion in prostate cancer cells. The researchers found that the gene fusion blocks the androgen receptor directly and also interferes with it at the genetic level to prevent normal androgen receptor signaling. With the androgen receptor blocked, prostate cells stop growing and developing normally, allowing cancer to develop.

"Our study shows the underlying problem in prostate cancer is the presence of a gene fusion, not the androgen receptor. In many contexts, androgen signaling is actually a good thing, but the presence of the gene fusion blocks androgen receptor signaling, which alters normal prostate cell development. While current treatments for advanced prostate cancer are focused on hormone deprivation and are quite effective, at least initially, future therapies need to be developed that target the prostate cancer gene fusion," Chinnaiyan says.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related biology news :

1. Inflammation triggers cell fusions that could protect neurons, Stanford research shows
2. Children living in apartments with nonsmoking adults still exposed
3. Smoking during radiation therapy for head and neck cancers linked to poorer outcomes
4. GUMC to develop smoking cessation aids based on unconventional nicotine addiction theory
5. Obesity and passive smoking reduce oxygen supply to unborn baby
6. Acculturation affects smoking cessation success among Latinos
7. Cigarette smoking increases colorectal cancer risk
8. Second-hand smoking results in liver disease, study finds
9. Study: Smoking may worsen malnutrition in developing nations
10. New mediator of smoking recruits
11. Smoking during pregnancy may impair thyroid function of mom and fetus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene fusions may be the 'smoking gun' in prostate cancer development, U-M study finds
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
Breaking Biology Technology: